These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23110398)

  • 1. Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.
    Lohr V; Genzel Y; Jordan I; Katinger D; Mahr S; Sandig V; Reichl U
    BMC Biotechnol; 2012 Oct; 12():79. PubMed ID: 23110398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
    Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
    Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.
    Genzel Y; Vogel T; Buck J; Behrendt I; Ramirez DV; Schiedner G; Jordan I; Reichl U
    Vaccine; 2014 May; 32(24):2770-81. PubMed ID: 24583003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
    George M; Farooq M; Dang T; Cortes B; Liu J; Maranga L
    Biotechnol Bioeng; 2010 Aug; 106(6):906-17. PubMed ID: 20589670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells.
    Hussain AI; Cordeiro M; Sevilla E; Liu J
    Vaccine; 2010 May; 28(22):3848-55. PubMed ID: 20307595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the "von Magnus effect".
    Tapia F; Wohlfarth D; Sandig V; Jordan I; Genzel Y; Reichl U
    PLoS One; 2019; 14(11):e0224317. PubMed ID: 31689309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.
    Vázquez-Ramírez D; Jordan I; Sandig V; Genzel Y; Reichl U
    Appl Microbiol Biotechnol; 2019 Apr; 103(7):3025-3035. PubMed ID: 30796494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an efficient veterinary rabies vaccine production process in the avian suspension cell line AGE1.CR.pIX.
    Trabelsi K; Zakour MB; Jordan I; Sandig V; Rourou S; Kallel H
    BMC Biotechnol; 2022 Jun; 22(1):17. PubMed ID: 35715843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.
    Chen A; Poh SL; Dietzsch C; Roethl E; Yan ML; Ng SK
    BMC Biotechnol; 2011 Aug; 11():81. PubMed ID: 21835017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line.
    Peschel B; Frentzel S; Laske T; Genzel Y; Reichl U
    Vaccine; 2013 Nov; 31(48):5693-9. PubMed ID: 24113260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
    Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP
    PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor.
    Chu C; Lugovtsev V; Lewis A; Betenbaugh M; Shiloach J
    Vaccine; 2010 Oct; 28(44):7193-201. PubMed ID: 20800699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.
    Gränicher G; Coronel J; Pralow A; Marichal-Gallardo P; Wolff M; Rapp E; Karlas A; Sandig V; Genzel Y; Reichl U
    Vaccine; 2019 Nov; 37(47):7019-7028. PubMed ID: 31005427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of MDCK cells for production of live attenuated influenza vaccine.
    Liu J; Shi X; Schwartz R; Kemble G
    Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selected problems of manufacturing influenza vaccines].
    Augustynowicz E
    Przegl Epidemiol; 2010; 64(3):373-80. PubMed ID: 20976949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates.
    Boonnak K; Paskel M; Matsuoka Y; Vogel L; Subbarao K
    Vaccine; 2012 Aug; 30(38):5603-10. PubMed ID: 22789506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine.
    Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture.
    Genzel Y; Fischer M; Reichl U
    Vaccine; 2006 Apr; 24(16):3261-72. PubMed ID: 16472544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor.
    Tapia F; Vogel T; Genzel Y; Behrendt I; Hirschel M; Gangemi JD; Reichl U
    Vaccine; 2014 Feb; 32(8):1003-11. PubMed ID: 24269322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation.
    Genzel Y; Dietzsch C; Rapp E; Schwarzer J; Reichl U
    Appl Microbiol Biotechnol; 2010 Sep; 88(2):461-75. PubMed ID: 20617311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.